<DOC>
	<DOCNO>NCT02564198</DOCNO>
	<brief_summary>The main purpose study evaluate safety study drug know ramucirumab child recurrent refractory solid tumor include central nervous system ( CNS ) tumor .</brief_summary>
	<brief_title>A Study Ramucirumab ( LY3009806 ) Children With Refractory Solid Tumors</brief_title>
	<detailed_description />
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Ramucirumab</mesh_term>
	<mesh_term>Endothelial Growth Factors</mesh_term>
	<criteria>Part A : participant recurrent refractory nonCNS solid tumor Part B : participant recurrent refractory CNS tumor Measurable evaluable disease No therapeutic option Performance Status : Karnofsky ≥50 % participant &gt; 16 year Lansky ≥50 participant ≤16 year Active recent history serious bleed event Active recent history gastrointestinal perforation , ulcer , fistulas abscess Active recent history hypertensive crisis hypertensive encephalopathy Active nonhealing wound bone fracture History solid organ transplant</criteria>
	<gender>All</gender>
	<minimum_age>12 Months</minimum_age>
	<maximum_age>21 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>relapse pediatric solid tumor</keyword>
	<keyword>unspecified childhood solid tumor</keyword>
	<keyword>brain central nervous system tumor</keyword>
</DOC>